I’m not doubting your numbers, but I am querying your description of breakeven after EBITDA and but not NPAT.
Eye would have years of deferred losses and capital and research expenditure. It will be years before Eye starts paying company tax. Even if eye didn’t have deferred tax credits then If eye is break even for ebitda then it will only pay 25% tax on the EBITDA figure. This leaves a pretty healthy NPAT.
fun times ahead, looks like our Handbreak of 21 cents is slowly being released. Discounted CR always suck , but we’re cashed up to keep growing sales and yes hopefully cashflow neutral of profitable soon.
GLTA,
Nova Eye Medical (EYE) Discussion, page-2482
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.005(1.92%) |
Mkt cap ! $60.63M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.5¢ | 25.0¢ | $37.10K | 142.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34925 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 50 | 1 |
View Market Depth
| Last trade - 11.10am 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
26.5¢ |
Change
0.005 ( 6.00 %) |
||||
| Open | High | Low | Volume | ||
| 25.5¢ | 26.5¢ | 25.5¢ | 49723 | ||
| Last updated 11.36am 13/05/2024 ? | |||||
| EYE (ASX) Chart |